The Incidence of Cervical Disease in Women of Different Age Groups in the Republic of Sakha (Yakutia)

Maria P. Kirillina, Sargylana I. Sofronova, Irina V. Kononova, Anna K. Ivanova, Darima K. Garmaeva, Elena L. Lushnikova

International Journal of Biomedicine. 2019;9(1):39-42.
DOI: 10.21103/Article9(1)_OA7
Originally published March 15, 2019


The purpose of this study was to investigate the incidence of cervical disease in women of different age groups in the Republic of Sakha (Yakutia).
Materials and Methods: The cytological material of the cervix of 7,600 women aged between 18 and 88 years was analyzed in the laboratory of pathomorphology, histology and cytology. The material of the cytological study consisted of smears of cervical mucosa and the cervical canal, stained according to the method of Romanovsky-Giemsa. The study was conducted with subjects grouped according to age: Group 1 (18-29), Group 2 (30-44), Group 3 (45-59), and Group 4 (60-74).
Results: According to the results of cytological analysis, inflammatory diseases of the cervix uteri were diagnosed in 4,629/61% cases. Among age groups, the highest rate of inflammatory diseases of the cervix uteri was registered in Group 1 and Group 2. Benign cervical lesions were found in 563/7.4% cases with the highest incidence in Groups 1 and 2. The most frequently diagnosed pathology was squamous cell metaplasia with maximum frequency in Group 2 and Group 1. Cervical intraepithelial neoplasia (or dysplasia) (CIN) was detected in 359/4.7% cases. CIN I, CIN II and CIN III were registered in 220/61.3%, 84/24.5%, and 38/10.6% women, respectively. At the same time, the maximum frequency of dysplasia was noted in Group 1 and Group 2. Thus, results obtained indicate a high incidence of cervical disease in women of reproductive age.

cervical disease • inflammatory diseases • benign cervical lesions • cervical intraepithelial neoplasia
  1. Prilepskaya V. N. Cervix uteri, vulva and vagina diseases: Clinical lectures, V.3, М.: Medpressform, 2003.
  2. WHO. Human papillomavirus (HPV) and cervical cancer. 15 February 2018. Available from:
  3. Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, et al.; International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003 Feb 6;348(6):518-27.
  4. Park KJ, Soslow RA. Current concepts in cervical pathology. Arch Pathol Lab Med. 2009 May;133(5):729-38. doi: 10.1043/1543-2165-133.5.729.
  5. Bokhman JV. Clinic and treatment of cervical cancer. Chisinau: Shtiints;1976. [In Russian].
  6. Papanicolaou G, Traut H. Diagnostic value of vaginal smears in carcinoma of uterus. Am J Obstet Gynecol. 1941;42:193–206. 
  7. Gibb RK, Martens MG. The impact of liquid-based cytology in decreasing the incidence of cervical cancer. Rev Obstet Gynecol. 2011;4(Suppl 1):S2-S11.
  8. Sawaya GF. Rightsizing cervical cancer screening: comment on "Cervical cancer screening with both human papillomavirus and Papanicolaou testing vs Papanicolaou testing alone". Arch Intern Med. 2010;170(11):985-6. doi: 10.1001/archinternmed.2010.133.
  9. US Preventive Services Task Force, Curry SJ, Krist AH, Owens DK, Barry MJ, Caughey AB, Davidson KW, et al. Screening for Cervical Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2018 Aug 21;320(7):674-686. doi: 10.1001/jama.2018.10897.

Download Article
Received December 10, 2018.
Accepted January 21, 2019.
©2019 International Medical Research and Development Corporation.